Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders Alline Cristina Campos, Fabricio Araujo Moreira, Felipe Villela Gomes, Elaine Aparecida Del Bel and Francisco Silveira Guimaraes Philosophical Transactions of The Royal Society Bulletin, 2012, 367, 3364–3378 doi:10.1098/rstb.2011.0389 Abstract Cannabidiol (CBD) is amajor phytocannabinoid present in the Cannabis sativa plant. It lacks the psychotomimetic and other psychotropic effects that the main plant compound D9 tetrahydrocannabinol (THC) being able, on the contrary, to antagonize these effects. This property, together with its safety profile, was an initial stimulus for the investigation of CBD pharmacological properties. It is now clear thatCBDhas therapeutic potential over a [...]
Lire la suiteCannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia : A Multicenter Randomized Controlled Trial Philip Mc Guire, Philip Robson, Wieslaw Jerzy Cubala, Daniel Vasile, Paul Dugald Morrison, Rachel Barron, Adam Taylor, Stephen Wright, American Journal of Psychiatry, 2018, 175, 3, 225-231 https://doi.org/10.1176/appi.ajp.2017.17030325 Abstract Objective: Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed the safety and effectiveness of CBD in patients with schizophrenia. Method: In an exploratory double-blind parallel-group trial, patients with schizophrenia were randomized in a 1:1 ratio to receive CBD (1000 mg/day; N=43) or placebo (N=45) alongside their existing antipsychotic medication. Participants were assessed before and after treatment using [...]
Lire la suiteMedical Cannabis Use in Glioma Patients Treated at a Comprehensive Cancer Center in Florida Maija Reblin, Solmaz Sahebjam, Noah C. Peeri, Yessica C. Martinez, Zachary Thompson, and Kathleen M. Egan. Journal of Palliative Medicine, 2019, May 13 https://doi.org/10.1089/jpm.2018.0528 Abstract : Background: Glioma is a devastating primary tumor of the central nervous system with difficult-to-manage symptoms. Cannabis products have been postulated to potentially benefit glioma patients. Recent state legalization allowed investigators an opportunity to study glioma patients' adoption of medical marijuana (MM). Objective: Our goals were to: (1) determine the prevalence of marijuana use, both through physician recommendation and self-medication, and (2) evaluate its perceived risks and [...]
Lire la suiteCannabidiol Enhances the Therapeutic Effects of TRAIL by Upregulating DR5 in Colorectal Cancer Jung Lim Kim, Bo Ram Kim, Dae Yeong Kim, Yoon A. Jeong, Soyeon Jeong, Yoo Jin Na, Seong Hye Park, Hye Kyeong Yun, Min Jee Jo, Bu Gyeom Kim, Han Do Kim, Dae Hyun Kim, Sang Cheul Oh, Sun Il Lee and Dae-Hee Lee Cancers, 2019, 11, 642 DOI : 10.3390/cancers11050642 www.mdpi.com/journal/cancers Abstract : Cannabidiol, a major non-psychotomimetic compound derived from Cannabis sativa, is a potential therapeutic agent for a variety of diseases such as inflammatory diseases, chronic neurodegenerative diseases, and cancers. Here, we found that the combination of cannabidiol and TNF-related [...]
Lire la suiteMDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials Michael C. Mithoefer, Allison A. Feduccia, Lisa Jerome, Anne Mithoefer, Mark Wagner, Zach Walsh, Scott Hamilton, Berra Yazar-Klosinski, Amy Emerson, Rick Doblin Psychopharmacology, 2019 https://doi.org/10.1007/s00213-019-05249-5 Abstract Background : Posttraumatic stress disorder is a prevalent mental health condition with substantial impact on daily functioning that lacks sufficient treatment options. Here we evaluate six phase 2 trials in a pooled analysis to determine the study design for phase 3 trials of MDMA-assisted psychotherapy for PTSD. Methods : Six randomized, double-blind, controlled clinical trials [...]
Lire la suiteEfficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study Vanina Popova, M.D., Ella J. Daly, M.D., Madhukar Trivedi, M.D., Kimberly Cooper, M.S., Rosanne Lane, M.A.S., Pilar Lim, Ph.D., Christine Mazzucco, M.Sc., David Hough, M.D., Michael E. Thase, M.D., Richard C. Shelton, M.D., Patricio Molero, M.D., Ph.D., Eduard Vieta, M.D., Ph.D., Malek Bajbouj, M.D., Husseini Manji, M.D., Wayne C. Drevets, M.D., Jaskaran B. Singh, M.D. American Journal of Psychiatry in Advance, 2019 ajp.psychiatryonline.org doi: 10.1176/appi.ajp.2019.19020172 Objective : About one-third of patients with depression fail to achieve remission despite treatment with multiple [...]
Lire la suiteCannabidiol, a Cannabis sativa constituent, as an antipsychotic drug A.W. Zuardi, J.A.S. Crippa, J.E.C. Hallak, F.A. Moreira and F.S. Guimarães Brazilian Journal of Medical and Biological Research, 2006, 39, 421-429 ISSN 0100-879X Review Abstract A high dose of Δ9-tetrahydrocannabinol, the main Cannabis sativa (cannabis) component, induces anxiety and psychotic-like symptoms in healthy volunteers. These effects of Δ9-tetrahydrocannabinol are significantly reduced by cannabidiol (CBD), a cannabis constituent which is devoid of the typical effects of the plant. This observation led us to suspect that CBD could have anxiolytic and/or antipsychotic actions. Studies in animal models and in healthy volunteers clearly suggest an anxiolytic-like effect of CBD. The [...]
Lire la suiteCannabis for refractory epilepsy in children : a review focusing on CDKL5 Deficiency Disorder Tristan Dale, Jenny Downs, Heather Olson, Ann Marie Bergin, Stephanie Smith and Helen Leonard Epilepsy Research, 2019 DOI: https://doi.org/doi:10.1016/j.eplepsyres.2019.02.001 Abstract Severe paediatric epilepsies such as CDKL5 Deficiency Disorder (CDD) are extremely debilitating, largely due to the early-onset and refractory nature of the seizures. Existing treatment options are often ineffective and associated with a host of adverse effects, causing those that are affected to seek alternative treatments. Cannabis based products have attracted significant attention over recent years, primarily driven by reports of miraculous cures and a renewed public preference for ‘natural’ therapies, [...]
Lire la suiteA role for cannabidiol in psychiatry? Keep calm and follow the drug development rules Gabriella Gobbi THE WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2019, VOL. 20, NO. 2, 98–100 Commentary https://doi.org/10.1080/15622975.2019.1584680 Along with tetrahydrocannabinol (THC), cannabidiol (CBD) is one of the main pharmacological components of Cannabis sativa and indica. Unlike THC, which binds CB1 receptors, CBD does not cause any dependence, and acts mostly via 5-HT1A and TPRV1 receptors (De Gregorio et al. 2018). Khoury et al. (2019) recently published a systematic review on the role of cannabidiol in psychiatry in the World Journal of Biological Psychiatry. After analysing 609 articles, they found six case reports, [...]
Lire la suiteEffects of Cannabidiol and a Novel Cannabidiol Analog against Tactile Allodynia in a Murine Model of Cisplatin-Induced Neuropathy: Enhanced Effects of Sub-Analgesic Doses of Morphine Hannah Marie Harris, Waseem Gul, Mahmoud A. ElSohly, Kenneth J. Sufka Medical Cannabis and Cannabinoids, 2018, 1, 54–59 Preclinical Science and Clinical Studies – Research Article DOI: 10.1159/000489077 Abstract Objective : This research examined whether a cannabidiol (CBD)-opioid pharmacotherapy could attenuate cisplatin-induced tactile allodynia. Methods : Mice (C57BL/6) were given 6 doses of 2.3 mg/kg cisplatin intraperitoneally (IP) on alternating days to induce tactile allodynia as quantified using an electric von Frey (eVF). Test groups in Experiment 1 received either vehicle, 0.1 [...]
Lire la suite